Actively Recruiting
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Led by Corcept Therapeutics · Updated on 2026-02-11
8
Participants Needed
1
Research Sites
36 weeks
Total Duration
On this page
Sponsors
C
Corcept Therapeutics
Lead Sponsor
U
University of Missouri-Columbia
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
CONDITIONS
Official Title
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- AST > 17 U/L for women and AST > 20 U/L for men, unless a qualifying liver biopsy within 12 months shows specific NAFLD Activity Scores and fibrosis levels
- MRI-PDFF showing at least 8% liver fat, performed within 4 weeks before baseline
- Presence of at least one metabolic syndrome characteristic increasing MASH risk, such as type 2 diabetes managed with diet or stable metformin, or three or more metabolic syndrome components including elevated blood glucose, blood pressure, triglycerides, low HDL cholesterol, or overweight/obesity
You will not qualify if you...
- Participation in another clinical trial for MASH or weight loss within the last 3 months
- Participation in any clinical trial within the last 3 months or 5 half-lives of treatment, whichever is longer
- Women who are pregnant, planning pregnancy, or breastfeeding
- BMI less than 18 kg/m2 or greater than 45 kg/m2
- Significant alcohol use exceeding 20 g/day for women or 30 g/day for men within 1 year prior to screening
- Positive urine drug screen for amphetamines, cocaine, opiates, or cannabinoids
- Known or suspected liver cirrhosis or signs of liver failure
- Other chronic liver diseases such as hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, or Wilson's disease
- History of recent heart attack, unstable angina, or stroke within 3 months
- Uncontrolled high blood pressure (systolic > 160 mm Hg or diastolic > 100 mm Hg)
- Current use of medications that may interact with the study drug
- Contraindications to MRI scanning
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Missouri
Columbia, Missouri, United States, 65211
Actively Recruiting
Research Team
E
Elizabeth Parks, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here